Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Data from BASECAMP expected in Q1 2027 Data from BASECAMP expected in Q1 2027
Data from BASECAMP expected in Q1 2027 Data from BASECAMP expected in Q1 2027